Quick Facts: Uses and Domains

• Bone Health: Management of serious bone complications related to advanced cancer.
• Cancer Support: Prevention of skeletal-related events in individuals with multiple myeloma.
• Specific Tumors: Treatment option for giant cell tumor of bone.
• Calcium Levels: Management of high blood calcium levels (hypercalcemia of malignancy) that have not responded to bisphosphonate therapy.

---

Main Uses and Therapeutic Benefits

Эксджива (Denosumab) is approved for several important therapeutic domains, primarily involving the reduction of complications related to bone disease. The medication is used to prevent skeletal-related events in patients who have bone metastases from solid tumors, such as breast or prostate cancer. Skeletal-related events may include fractures, spinal cord compression, or the requirement for radiation or surgery to the bone.

Additionally, this prescription treatment is indicated for the prevention of these same serious bone problems in individuals living with multiple myeloma. The drug is also approved for the management of giant cell tumor of bone in adults and in skeletally mature adolescents, particularly when the tumor cannot be removed surgically or when surgery may result in significant health issues.

Finally, Эксджива may be prescribed to address high levels of calcium in the blood caused by malignancy (hypercalcemia of malignancy) in cases where other approved treatments have not achieved the intended response.

Eligibility Map: Who can and cannot use Эксджива (Xgeva) — Official Regulatory Information

The eligibility profile for Xgeva (denosumab) is defined by a set of absolute contraindications and population-specific restrictions documented in official regulatory labeling.

Classification	Regulatory Statement
Contraindicated	Known hypersensitivity to the drug or components; uncorrected pre-existing hypocalcemia; and use in pregnant women due to risk of fetal harm.
Use Restricted	Patients with severe renal impairment (CrCl < 30 mL/min) or those on dialysis are eligible but require intensive calcium and vitamin D monitoring and supplementation due to increased hypocalcemia risk.
Use Not Recommended	Pediatric patients (age < 18) are not generally recommended for treatment. The single exception is for skeletally mature adolescents (aged 12-17 years) with unresectable Giant Cell Tumor of Bone.
Special Consideration	Lactating women must weigh the benefits and risks, leading to a decision to discontinue nursing or discontinue the drug. Women of childbearing potential are required to use effective contraception during and for at least 5 months following the last dose.

Eligibility also requires a pre-treatment oral examination, and patients should avoid receiving Xgeva alongside other denosumab products.

Interactions with other medicines and products

Official Regulatory Interaction Profile

The regulatory profile for Эксджива (Denosumab) is defined by a lack of metabolic drug interactions and specific pharmacodynamic constraints related to mineral balance. As a monoclonal antibody, Denosumab is not expected to alter the pharmacokinetics of small-molecule medicines metabolized by the Cytochrome P450 (CYP) enzyme systems, a finding supported by clinical studies that showed no effect on the CYP3A4 substrate midazolam.

---

Documented Interaction Constraints

Classification	Constraint / Affected Product	Regulatory Statement
Formal Restriction	Other Denosumab-containing products (e.g., Prolia)	Co-administration is formally restricted to prevent cumulative exposure and is generally considered a contraindicated combination.
Pharmacodynamic Risk	Calcimimetic drugs	Concomitant use may worsen the risk of hypocalcemia due to additive effects on calcium levels.
Population-Specific Risk	Severe renal impairment/dialysis patients	Risk of developing severe hypocalcemia is heightened in these patient populations.

---

Supplementation Requirement

Official labeling mandates that calcium and Vitamin D supplementation is required for all patients receiving Denosumab to mitigate the risk of hypocalcemia. No specific interactions are documented with food, alcohol, or herbal products.

Blocking the Bone Breakdown Signal (RANKL Inhibition)

The drug is a monoclonal antibody that functions as a selective inhibitor by binding with high affinity to RANK Ligand ( RANKL). This molecular interaction blocks RANKL from engaging its receptor ( RANK) on the surface of bone breakdown cells ( osteoclasts) and their precursors. This blockade suppresses the RANKL/ RANK signaling pathway, which is essential for osteoclast formation, function, and survival.

---

Modulating the Bone Remodeling Balance

By disrupting this specific signaling cascade, the drug achieves a system-level physiological modulation: a decrease in the rate of bone resorption. This action shifts the natural equilibrium of bone turnover toward preservation, without directly stimulating bone formation. The resulting maintenance of existing bone mass and microstructure is the direct physiological consequence of the RANKL inhibition mechanism.

Administration Process

The administration of this medication is performed by a healthcare professional. It is delivered as an injection under the skin (subcutaneously). Common sites for the injection include the upper arm, the upper thigh, or the abdomen.

Preparation and Handling

Prior to use, the solution is visually inspected for the presence of particulate matter or discoloration. The medication should typically be allowed to reach room temperature before administration to ensure patient comfort. It is important that the product is handled according to clinical standards to maintain its integrity.

Routine and Monitoring

Care is usually coordinated within a clinical setting to ensure consistent application. Healthcare providers may monitor specific health markers during the course of the use of this medication to track the body's response. Patients are encouraged to maintain a regular schedule as determined by their healthcare provider and to discuss any practical aspects of the administration process during their appointments.

Research evidence / Overview of studies for Эксджива

This section summarizes the published research available for Эксджива (denosumab), focusing only on the structure of the studies and what has been measured, without offering medical advice, treatment promises, or instructions for use. Findings describe group patterns and do not predict individual outcomes.

---

1. Исследование эффективности в профилактике костных осложнений (SREs)

This section will summarize the structure of the main Phase 3 Randomized Controlled Trials (RCTs) for patients with костные метастазы (bone metastases) от солидных опухолей, describing the study designs, the specific outcomes researchers measured (like time to a fracture or bone surgery), and the types of cancer patients included in these studies.

The available research for Эксджива in bone metastases includes large-scale, multi-national Randomized Controlled Trials (RCTs). These studies were designed to explore patterns related to Эксджива administration; an active comparator, most commonly zoledronic acid, was used in the trials. These research efforts were applied in studies examining patient-reported experiences related to bone complications.

The main focus of these trials was the measurement of the time to first skeletal-related event (SRE). SREs are outcomes related to physical discomfort and systemic or functional imbalance, such as a pathological fracture (a break in the bone), the need for radiation therapy to the bone, or surgery required to treat bone damage. Trials also monitored outcomes related to physical discomfort, such as changes in pain intensity as reported by patients. Findings describe patterns observed in the studies related to the timing of these events in the observed populations. Research monitored time to the first SRE across the study groups receiving Эксджива or the comparator drug.

---

2. Области неопределенности и дальнейшие потребности в исследованиях

This final section will synthesize the основные пробелы в данных (evidence gaps) и области неопределенности (uncertainty), as noted by researchers and regulatory bodies. It will clarify where more research is needed, such as the full long-term effects, the consequences of treatment cessation, and direct comparisons with all alternative therapies.

Several research limitations frames exist within the current evidence landscape. The long-term effects are not fully established for either indication, particularly regarding outcomes years after administration has stopped. Research is ongoing to provide insight into short-term changes after cessation. For bone metastases, while the primary RCTs compared Эксджива to zoledronic acid, comparative evidence is lacking against other alternative therapies that were not included in the main trials.

For гигантоклеточная опухоль кости (GCTB), certainty remains low regarding the optimal duration of administration before surgery, and studies focusing on episodes where symptoms become more noticeable after stopping the drug are still evolving. The available data for certain groups, such as children who are not skeletally mature, remain insufficient. Study results reflect the specific conditions under which they were conducted. Findings describe group patterns, not personal outcomes, and evidence helps contextualize what has been observed so far, highlighting what is known—and what is still uncertain.

Key Studies & References

1. Pharmacokinetics and Pharmacodynamics of Denosumab in Subjects with Varying Degrees of Renal Function

Common questions about Эксджива (FAQ)

Q: What is Эксджива used for?

A: Эксджива (denosumab) is approved for use in adults with certain advanced cancers that have spread to the bone. It is used to help reduce the risk of serious bone problems, such as fractures, that can be caused by the spread of cancer to the bone. It is also approved for the treatment of giant cell tumor of the bone that cannot be treated with surgery or where surgery would cause significant problems.

---

Q: How does Эксджива work?

Because Эксджива is a monoclonal antibody, it is designed to target a specific protein in the body. It works by attaching to a protein called RANKL. This action reduces the activity of cells that break down bone tissue, which can help strengthen the bone. The cells in giant cell tumors of the bone are also affected by this mechanism.

---

Q: Does Эксджива cause low calcium levels (hypocalcemia)?

A: Yes, low calcium levels have been observed in some individuals receiving Эксджива. This effect can be serious. Patients may be advised by their healthcare provider to take calcium and vitamin D supplements to help manage this risk. Low calcium levels can be associated with symptoms like muscle spasms, tingling sensations, and confusion.

---

Q: What are the common side effects of Эксджива?

Side effects that were commonly reported in clinical studies include:

• Back, arm, or leg pain
• Fatigue or weakness
• Low phosphate levels in the blood
• Headache
• Diarrhea

Not all individuals will experience these effects. A healthcare provider can discuss the full range of potential side effects and risks.

How to Store and Dispose of Xgeva (Denosumab)

Official regulatory documentation outlines specific requirements for storing and handling Xgeva, a biologic medicine.

Storage Requirements

Xgeva must be stored under refrigerated conditions, maintained between 2 C to 8 C (36 F to 46 F). It is mandatory to keep the product in its original outer carton to protect the solution from light. The medicine must not be frozen and should be kept out of the reach of children. Before use, the product may be allowed to stand in the original container to reach room temperature (up to 25 C) for up to 30 minutes; it must not be warmed in any other way.

Disposal Instructions

Xgeva is provided as a single-use vial or pre-filled syringe. The container must be discarded immediately after use or the first entry. Unused medicine, expired product, and all associated waste material must be disposed of in accordance with local regulations for pharmaceutical and sharps waste.